Mr. Rashid Bux reports

BIOMARK ANNOUNCES THE FINAL CLOSING OF OVERSUBSCRIBED PRIVATE PLACEMENT

Biomark Diagnostics Inc. has closed its previously announced oversubscribed non-brokered private placement.

The closing of the second and final tranche builds upon the momentum of the previously announced first tranche on March 26, 2025, culminating in a significantly successful financing round. This second tranche consisted of 4,593,984 units, bringing the total number of units issued in this financing round to 14,203,984. The units were issued at a price of 30 cents per unit for aggregate gross proceeds of $4,261,195. The financing will be utilized to accelerate Biomark's commercialization and for other corporate development goals.

Demonstrating strong investor confidence in Biomark's vision and technology, Biomark secured the additional subscriptions of up to 4,593,984 units at a price of 30 cents per unit for aggregate gross proceeds of up to $1,378,195. Each unit consists of one common share of Biomark and one full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share of Biomark at 50 cents per share for a period of three years from the closing date of the private placement. The warrants under the second tranche may be subject to an acceleration clause if the closing trading price of Biomark's shares is greater than $1 per common share for a period of 10 consecutive trading days. Biomark may, upon providing written notice to the holders of warrants, accelerate the expiry date of the warrants to the date that is 30 days following the date of such written notice. The securities issued under the private placement will be subject to a period of four months and one day under the Canadian securities laws and subject to resale restrictions under the U.S. securities laws. A debt conversion consisting of one million units in settlement of indebtedness in the aggregate amount of $300,000 to pay to the related party was also completed. No finders' fees were payable on the private placement.

The proceeds of the private placement will be used for key strategic initiatives toward commercialization of Biomark's liquid biopsy tests, including lab certification, hiring essential lab personnel such as a medical lab director and a quality assurance specialist, enhancement of data security infrastructure, and general operating expenditures. These investments are crucial for Biomark to advance its commercialization efforts, commence sales of its assay and expand its market reach.

Biomark's chief executive officer and president, Rashid Bux, commented: "We are delighted by the strong support from our existing strategic investors in the United States and Europe. Their investment, at a premium of over 20 per cent to the existing share price, is a significant vote of confidence in Biomark's team, technology and strategic direction. This validates the substantial advancements we've made over the past 12 months and fuels our potential for significant growth.

"We greatly appreciate this strong demonstration of support and confidence shown by our existing investors. These shareholders are well apprised of the current growth opportunities and near-term catalysts for Biomark, and their continued financial support has been key to our ability to pursue our business objectives for 2025 and beyond successfully."

He concluded, "We are at the cusp of commercialization and excited about the upcoming transformative milestones at Biomark."

Certain insiders, directors and officers subscribed for a portion of this placement. Participation of the insiders of the company in the private placement constitutes a related-party transaction as defined under Multilateral Instrument 61-101 (Protection of Minority Security Holders in Special Transactions). Because the company's shares trade only on the Canadian Securities Exchange, the issuance of securities is exempt from the formal valuation requirements of Section 5.4 of MI 61-101 pursuant to Subsection 5.5(b) of MI 61-101 and exempt from the minority approval requirements of Section 5.6 of MI 61-101. The company did not file a material change report 21 days prior to the closing of the private placement as the details of the participation of insiders of the company had not been confirmed at that time.

About Biomark Diagnostics Inc.

Biomark is a leading developer of liquid biopsy tests for the early detection of cancer which leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Biomark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.

We seek Safe Harbor.